Cabaletta Bio (CABA) Competitors $1.32 +0.04 (+3.13%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. ACB, DRUG, ATXS, SLRN, HUMA, ALMS, LFCR, SLDB, IMMP, and CDTXShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include Aurora Cannabis (ACB), Bright Minds Biosciences (DRUG), Astria Therapeutics (ATXS), Acelyrin (SLRN), Humacyte (HUMA), Alumis (ALMS), Lifecore Biomedical (LFCR), Solid Biosciences (SLDB), Immutep (IMMP), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Aurora Cannabis Bright Minds Biosciences Astria Therapeutics Acelyrin Humacyte Alumis Lifecore Biomedical Solid Biosciences Immutep Cidara Therapeutics Cabaletta Bio (NASDAQ:CABA) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Does the media favor CABA or ACB? In the previous week, Cabaletta Bio and Cabaletta Bio both had 4 articles in the media. Cabaletta Bio's average media sentiment score of 1.62 beat Aurora Cannabis' score of 0.60 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CABA or ACB? Cabaletta Bio presently has a consensus target price of $21.00, indicating a potential upside of 1,490.91%. Given Cabaletta Bio's higher possible upside, research analysts plainly believe Cabaletta Bio is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Is CABA or ACB more profitable? Aurora Cannabis has a net margin of 0.42% compared to Cabaletta Bio's net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat Cabaletta Bio's return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% Aurora Cannabis 0.42%0.59%0.42% Do insiders & institutionals believe in CABA or ACB? 47.6% of Aurora Cannabis shares are held by institutional investors. 9.9% of Cabaletta Bio shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer CABA or ACB? Aurora Cannabis received 289 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 72.52% of users gave Cabaletta Bio an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9572.52% Underperform Votes3627.48% Aurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% Which has better earnings & valuation, CABA or ACB? Aurora Cannabis has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.34-0.56Aurora Cannabis$320.81M0.81-$48.62M$0.0592.80 Which has more risk & volatility, CABA or ACB? Cabaletta Bio has a beta of 2.44, suggesting that its stock price is 144% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. SummaryAurora Cannabis beats Cabaletta Bio on 11 of the 17 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$66.98M$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.6130.4222.4418.48Price / SalesN/A498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book0.243.206.774.25Net Income-$67.68M-$72.35M$3.22B$248.23M7 Day Performance-1.49%3.57%3.25%3.29%1 Month Performance-14.84%0.17%0.01%2.42%1 Year Performance-87.60%-21.21%18.00%5.54% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio3.21 of 5 stars$1.32+3.1%$21.00+1,490.9%-87.8%$66.98MN/A-0.6150Positive NewsGap DownACBAurora Cannabis0.6478 of 5 stars$4.16-6.3%N/A-26.6%$233.85M$320.81M83.221,340News CoverageDRUGBright Minds Biosciences3.309 of 5 stars$32.85-0.8%$84.33+156.7%+2,747.0%$231.40MN/A-193.22N/ANews CoveragePositive NewsGap DownATXSAstria Therapeutics2.8088 of 5 stars$4.07+0.7%$26.60+553.6%-44.0%$229.69MN/A-1.9530Analyst ForecastNews CoveragePositive NewsSLRNAcelyrin2.9921 of 5 stars$2.27+3.2%$9.60+322.9%-42.2%$229.06MN/A-0.92135Positive NewsHUMAHumacyte2.7912 of 5 stars$1.46-13.4%$13.71+842.6%-65.0%$225.70M$1.57M-1.09150News CoverageGap DownALMSAlumis2.5442 of 5 stars$4.76-4.8%$26.00+446.2%N/A$224.78MN/A0.00N/AAnalyst ForecastLFCRLifecore Biomedical1.6195 of 5 stars$6.03-5.9%$8.00+32.7%-1.5%$223.26M$130.86M-10.77690SLDBSolid Biosciences3.9854 of 5 stars$2.87+12.5%$15.67+445.9%-65.3%$222.41M$8.09M-0.94100News CoverageIMMPImmutep1.8043 of 5 stars$1.52-1.3%$8.50+459.2%-35.2%$221.98M$5.14M0.002,021News CoverageCDTXCidara Therapeutics4.3364 of 5 stars$20.15+3.7%$39.14+94.3%+71.4%$220.70M$1.28M-0.7990Analyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies ACB Competitors DRUG Competitors ATXS Competitors SLRN Competitors HUMA Competitors ALMS Competitors LFCR Competitors SLDB Competitors IMMP Competitors CDTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
